| First Author | Bode AM | Year | 2009 |
| Journal | Cancer Res | Volume | 69 |
| Issue | 3 | Pages | 905-13 |
| PubMed ID | 19155296 | Mgi Jnum | J:144978 |
| Mgi Id | MGI:3833038 | Doi | 10.1158/0008-5472.CAN-08-3263 |
| Citation | Bode AM, et al. (2009) Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res 69(3):905-13 |
| abstractText | Blockade of the transient receptor potential channel vanilloid subfamily 1 (TRPV1) is suggested as a therapeutic approach to pain relief. However, TRPV1 is a widely expressed protein whose function might be critical in various nonneuronal physiologic conditions. The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is overexpressed in many human epithelial cancers and is a potential target for anticancer drugs. Here, we show that TRPV1 interacts with EGFR, leading to EGFR degradation. Notably, the absence of TRPV1 in mice results in a striking increase in skin carcinogenesis. The TRPV1 is the first membrane receptor shown to have a tumor-suppressing effect associated with the down-regulation of another membrane receptor. The data suggest that, although a great deal of interest has focused on TRPV1 as a target for pain relief, the chronic blockade of this pain receptor might increase the risk for cancer development. |
